Advertisement

Tumor Biology

, Volume 34, Issue 6, pp 4027–4032 | Cite as

Association between NQO1 C609T polymorphism and colorectal cancer risk

  • Yongbing Wang
  • Genfu Zhang
  • Yunbao Luo
Research Article
  • 133 Downloads

Abstract

NAD(P)H: quinone oxidoreductase 1 (NQO1) is a cytosolic enzyme, and the NQO1 C609T polymorphism is associated with the enzymatic activity of NQO1. Many studies were performed to assess the association between NQO1 C609T polymorphism and colorectal cancer risk, but no consensus was available up to now. We conducted a meta-analysis to examine the association between NQO1 C609T polymorphism and colorectal cancer risk, and the pooled odds ratios (OR) with their 95 % confidence intervals (95 % CI) were used to assess the association. Finally, 12 studies involving 4,026 cases and 4,855 controls were included into the meta-analysis. Overall, there was an obvious association between NQO1 C609T polymorphism and colorectal cancer risk (T versus C: OR = 1.28, 95 % CI 1.08–1.51, P = 0.005; TT versus CC: OR = 1.60, 95 % CI 1.10–2.33, P = 0.015; TT/CT versus CC: OR = 1.36, 95 % CI 1.09–1.69, P = 0.006; TT versus CT/CC: OR = 1.37, 95 % CI 1.05–1.80, P = 0.022). Subgroup analysis by ethnicity showed that the association was obvious in both Caucasians and Asians. Therefore, the meta-analysis provides strong evidence for the association between NQO1 C609T polymorphism and colorectal cancer risk, and the T allele of NQO1 C609T polymorphism is an important risk factor of colorectal cancer.

Keywords

Colorectal cancer NQO1 Polymorphism Meta-analysis 

Notes

Funding

Sponsored by Shanghai Pudong New Area Key Discipline Foundation (grant no. PWZxk2010-01)

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Papagiorgis P: Colorectal cancer: Dichotomous or continuum model? Perhaps, a combination of both. Gut 2013Google Scholar
  3. 3.
    Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.PubMedCrossRefGoogle Scholar
  4. 4.
    Stoffel EM, Chittenden A. Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high risk patients. Gastroenterology. 2010;139:1436–41. 1441 e1431.PubMedCrossRefGoogle Scholar
  5. 5.
    Vasiliou V, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum Genomics. 2006;2:329–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (nqo1, dt-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004;382:115–44.PubMedCrossRefGoogle Scholar
  7. 7.
    Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA. Nqo1 polymorphisms and de novo childhood leukemia: a huge review and meta-analysis. Am J Epidemiol. 2008;168:1221–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (nqo1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012;83:1033–40.PubMedCrossRefGoogle Scholar
  9. 9.
    van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, Wobbes T, et al. Role of epoxide hydrolase, Nad(P)H:quinone oxidoreductase, cytochrome p450 2e1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res. 2006;593:39–49.PubMedCrossRefGoogle Scholar
  10. 10.
    Harth V, Donat S, Ko Y, Abel J, Vetter H, Bruning T. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol. 2000;73:528–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, et al. NAD(P)H:quinone oxidoreductase 1 (nqo1) c609t polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol. 2002;7:103–8.PubMedGoogle Scholar
  12. 12.
    Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis. 2002;23:1839–49.PubMedCrossRefGoogle Scholar
  13. 13.
    Dai E, Lu Z, Shi J, Yu Y, Zhang J. The Nad(P)H:quinone oxidoreductase 1 gene polymorphism and its association with colorectal cancer. Chin J Clin Oncol. 2004;31:89–91.Google Scholar
  14. 14.
    Begleiter A, Hewitt D, Maksymiuk AW, Ross DA, Bird RP. A Nad(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2422–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A, Vodicka P, et al. Association between exposure-relevant polymorphisms in cyp1b1, ephx1, nqo1, gstm1, gstp1, and gstt1 and risk of colorectal cancer in a Czech population. Oncol Rep. 2010;24:1347–53.PubMedGoogle Scholar
  16. 16.
    Nisa H, Kono S, Yin G, Toyomura K, Nagano J, Mibu R, et al. Cigarette smoking, genetic polymorphisms, and colorectal cancer risk: the Fukuoka colorectal cancer study. BMC Cancer. 2010;10:274.PubMedCrossRefGoogle Scholar
  17. 17.
    Peng X, Jiang Y, Shi X, Hu Z, Zheng X. Relationship between nqo1 c609t gene polymorphism and risk of colorectal cancer. CHIN J PUBLIC HEALTH. 2010;26:1078–82.Google Scholar
  18. 18.
    Sameer AS, Shah ZA, Syeed N, Rasool R, Afroze D, Siddiqi MA. NAD(P)H:quinone oxidoreductase 1 (nqo1) pro187ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. Asian Pac J Cancer Prev. 2010;11:209–13.PubMedGoogle Scholar
  19. 19.
    Su XL, Yan MR, Yang L. Nqo1 c609t polymorphism correlated to colon cancer risk in farmers from western region of inner Mongolia. Chin J Cancer Res. 2012;24:317–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Peng XE, Jiang YY, Shi XS, Hu ZJ. Nqo1 609c > t polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population. Gene. 2013;521:105–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  22. 22.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  23. 23.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  24. 24.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  25. 25.
    Wang YH, Lee YH, Tseng PT, Shen CH, Chiou HY. Human Nad(P)H:quinone oxidoreductase 1 (nqo1) and sulfotransferase 1a1 (sult1a1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol. 2008;134:203–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Fu J, Chen BC. Relationship between genetic polymorphism of nqo1 and susceptibility to bladder cancer. J Chin Oncol. 2012;18:561–4.Google Scholar
  27. 27.
    Misra V, Grondin A, Klamut HJ, Rauth AM. Assessment of the relationship between genotypic status of a dt-diaphorase point mutation and enzymatic activity. Br J Cancer. 2000;83:998–1002.PubMedCrossRefGoogle Scholar
  28. 28.
    Siegel D, McGuinness SM, Winski SL, Ross D. Genotype–phenotype relationships in studies of a polymorphism in Nad(P)H:quinone oxidoreductase 1. Pharmacogenet. 1999;9:113–21.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of General SurgeryShanghai Pudong New Area People’s HospitalShanghaiChina

Personalised recommendations